Aplastic anemia is a rare bone marrow failure syndrome characterized by the inability of the bone marrow to produce an adequate number of blood cells, resulting in peripheral pancytopenia and bone marrow hypocellularity in the absence of neoplastic infiltration or significant fibrosis. The primary defect involves quantitative and functional loss of hematopoietic stem cells and progenitors, with simultaneous reduction of the erythroid, myeloid, and megakaryocytic lineages.
Clinically, it typically presents as decreased production anemia with reticulocytopenia, variably associated with neutropenia and thrombocytopenia, which respectively cause susceptibility to infection and bleeding risk. The severity of the disorder is related mainly to the depth of neutropenia and thrombocytopenia and to the speed with which bone marrow failure develops, making timely diagnostic evaluation and a therapeutic choice guided by age, severity, and donor availability for transplantation essential.
Aplastic anemia includes acquired and inherited forms, the latter comprising inherited bone marrow failure syndromes. In adult clinical practice, most cases are acquired and, even after a complete workup, are often classified as immune mediated without an identifiable trigger. This category does not imply the absence of a biological cause, but reflects the difficulty of attributing the initiating event to a documented exposure or infection despite a pathogenic mechanism dominated by autoimmunity directed against the stem cell compartment.
Among recognized acquired causes, toxic exposures, particularly to benzene and related solvents, play an important role. Risk is influenced by the intensity and duration of exposure, environmental ventilation, and personal protective measures, with interindividual variability also related to benzene biotransformation pathways and genetic susceptibility. In occupational settings, the history must specifically investigate industrial activities, painting, work involving solvents, fuels, and poorly ventilated environments.
Another category includes drugs associated with bone marrow aplasia, typically through rare idiosyncratic reactions that are not always dose dependent and have variable latency. Historically, chloramphenicol has been linked to cases of aplastic anemia; disorders associated with several drug classes have also been described, including some antiepileptic drugs, antithyroid drugs, antibiotics, and other medications capable of triggering an immune response or selective toxicity in the stem cell compartment. In this context, it is essential to distinguish epidemiologic associations from certain causality by reconstructing chronology, duration of exposure, any drug rechallenge, and alternative etiologies.
Ionizing radiation can cause bone marrow failure through direct DNA damage and stem cell depletion in a dose dependent manner. In therapeutic settings, persistent aplasia after radiotherapy is rare but possible, particularly when large volumes are irradiated or radiotherapy is combined with myelotoxic chemotherapy. In accidental or industrial settings, exposure may be higher and accompanied by other signs of radiation syndrome.
Among biological agents, some viral infections are associated with aplastic anemia, more often as triggers of a dysregulated immune response than through a direct cytopathic effect on the marrow. A distinct clinical entity is hepatitis associated aplastic anemia, in which pancytopenia typically develops several weeks or months after an episode of acute hepatitis, often without identification of a single responsible virus. In other cases, infections such as HIV or herpesviruses may contribute to cytopenias through multiple mechanisms, making an accurate differential diagnosis essential.
Autoimmune conditions and states of immune dysregulation may be associated with bone marrow failure, either as comorbidities or as a predisposing context. In addition, in a proportion of patients, aplasia is accompanied by small paroxysmal nocturnal hemoglobinuria clones, reflecting immune selective pressure on the stem cell compartment that favors the emergence of immune escape clones.
Finally, particularly in young patients and in cases with suggestive clinical signs, it is essential to consider inherited forms of bone marrow failure: Fanconi anemia, caused by DNA repair defects; dyskeratosis congenita and other telomere biology disorders, caused by defects in telomere maintenance; Shwachman-Diamond syndrome; and other syndromic disorders. Recognition of these forms substantially changes the therapeutic approach, the choice of transplant conditioning, and management of the risk of toxicity and secondary malignancies.
In acquired forms, the pathogenesis of aplastic anemia is dominated by an immune mediated process in which activated cytotoxic T lymphocytes recognize and damage the hematopoietic stem cell compartment. Clonal expansion of autoreactive T cell populations and production of proinflammatory cytokines, particularly interferon gamma and TNF alpha, profoundly alter the balance among stem cell survival, quiescence, and proliferation, promoting cell cycle arrest and programmed cell death. In parallel, functional impairment of immune tolerance pathways, including altered Treg function, contributes to maintaining the immune attack over time.
A crucial component of the injury is activation of proapoptotic pathways and proliferation inhibitory signals that affect both stem cells and committed progenitors. The result is progressive quantitative depletion of the hematopoietic compartment, with simultaneous reduction of erythropoiesis, granulopoiesis, and megakaryopoiesis. The bone marrow consequently becomes hypocellular with fatty replacement, without the infiltrative features seen in hematologic neoplasms and without the diffuse increase in reticulin typical of many fibrotic disorders.
The bone marrow microenvironment and stem cell niche, although generally not the primary event, modulate the extent of injury and recovery capacity. Persistent inflammation, oxidative stress, and altered interactions between stromal cells and progenitors may further reduce trophic support for residual hematopoiesis. Systemically, anemia increases compensatory signals such as erythropoietin, which tends to rise in response to hypoxia, but this response is ineffective because the marrow lacks a sufficient pool of precursors to translate the stimulus into increased red blood cell production. This dissociation between demand signals and production capacity is a cardinal pathophysiologic feature of the disease.
In recent years, genomic and cytogenomic studies have shown that a substantial proportion of patients have clonal hematopoiesis with somatic mutations in genes associated with myelodysplasia or with selective advantages under immune pressure. Mutations in genes such as DNMT3A and ASXL1 more often tend to expand over time and are associated with a greater risk of clonal evolution, whereas clones with PIGA mutations, producing the PNH phenotype, or BCOR/BCORL1 mutations may remain stable or regress after immunosuppression, consistent with a survival advantage in a hostile immune mediated environment. This biological stratification explains why aplastic anemia is not a static condition but a continuum in which selective pressure can lead over the long term to PNH, myelodysplastic syndrome, or acute leukemia.
In inherited forms, the pathophysiology converges on the same bone marrow failure phenotype, but the initiating defect is intrinsic: abnormalities of DNA repair, chromosomal instability, or telomere dysfunction make the stem cell compartment vulnerable to replicative and oxidative stress. In these patients, environmental or immune stimuli that would be tolerated by healthy individuals may precipitate more rapid exhaustion of the stem cell reserve, with important implications for differential diagnosis and treatment selection.
The clinical presentation reflects the combination and severity of the cytopenias. The history often reveals an insidious onset with fatigue, reduced exercise tolerance, exertional dyspnea, and palpitations related to anemia with reticulocytopenia. In patients with cardiopulmonary comorbidities, even a moderate reduction in hemoglobin can cause rapid worsening of functional capacity, whereas adaptation in younger individuals may mask severity until more advanced stages.
Thrombocytopenia manifests with mucocutaneous bleeding, epistaxis, gingival bleeding, menorrhagia, petechiae, and ecchymoses; with profound thrombocytopenia, bleeding risk rises substantially and gastrointestinal hemorrhage or, more rarely but with high severity, intracranial hemorrhage may occur. A clinically useful feature is that typical aplastic anemia does not produce a picture of hypersplenism with massive sequestration and, consequently, significant splenomegaly or marked lymphadenopathy suggests alternative diagnoses.
Neutropenia causes susceptibility to infections that may progress rapidly and may sometimes be paucisymptomatic, particularly when inflammation is attenuated by the lack of neutrophils. Fever, sore throat, oral ulcerations, skin infections, pneumonia, and sepsis may be the presenting manifestations and require urgent evaluation. Profound and prolonged neutropenia also increases the risk of invasive fungal infections, which contribute substantially to mortality if not recognized early.
Physical examination often reveals cutaneous and mucosal pallor, tachycardia, and signs of reduced peripheral perfusion. Cutaneous and mucosal bleeding manifestations must be sought systematically, as must signs of infection at less obvious sites. The presence of lymphadenopathy, marked hepatosplenomegaly, persistent bone pain, or signs of infiltration instead requires a broad differential approach because these findings are not part of the classic phenotype of aplastic anemia and may indicate leukemia, lymphoma, myelodysplasia, or other causes of pancytopenia.
Suspicion arises in the presence of a hypoproliferative cytopenia, particularly anemia with low reticulocytes, often associated with thrombocytopenia and neutropenia. First line evaluation includes a complete blood count with differential, reticulocyte count, and peripheral blood smear. In aplastic anemia, the smear generally shows cytopenias without marked dysplasia or circulating blasts; evident dysgranulopoiesis, pronounced macrocytosis with dysplasia, blasts, or atypical abnormalities suggests myelodysplasia or leukemia and requires targeted investigations.
In parallel, reversible causes or conditions that mimic pancytopenia must be excluded: assessment of liver and renal function, iron status, vitamin B12 and folate, hemolysis markers when indicated, inflammatory markers, and rational infectious disease screening that includes HIV and hepatitis viruses, as well as other viruses according to the clinical context. The medication and occupational history must be detailed because identification of relevant exposures may alter interpretation of the disorder and the management strategy.
Diagnostic confirmation requires bone marrow evaluation. Aspiration may be poorly representative when hypocellularity is marked, so bone marrow biopsy is essential to document hypocellularity, fatty replacement, and the absence of neoplastic infiltration or significant fibrosis. Concurrent cytogenetic and cytogenomic analyses help distinguish immune mediated aplastic anemia from hypocellular myelodysplasia, which can present with an overlapping phenotype but has different therapeutic and prognostic implications. Molecular evaluation may also support identification of inherited forms and establish the presence of clonal hematopoiesis.
An essential diagnostic step is screening for PNH clones by flow cytometry on granulocytes and monocytes. The presence of a PNH clone, even when small, is common in immune mediated bone marrow failure and provides useful prognostic and follow-up information, while also representing a feature of shared biology between aplastic anemia and PNH.
In severe or very severe forms, the workup must also include assessment of telomere length, regardless of age, and evaluation for somatic mutations; telomere assessment is particularly relevant in patients refractory to immunosuppression because it may identify a telomere biology disorder and alter the transplantation strategy.
Severity is classified using shared criteria that guide the urgency and intensity of treatment. In particular, severe aplastic anemia is defined by marked bone marrow hypocellularity associated with at least two significant cytopenias, with thresholds involving neutrophils, platelets, and reticulocytes; an additional category, very severe aplastic anemia, is distinguished by even more profound neutropenia associated with an extremely high infectious risk.
Commonly used severity classification (Camitta criteria and subsequent standardizations)
Definitive diagnosis is therefore based on coherent integration of hypoproliferative pancytopenia, hypocellular bone marrow, and systematic exclusion of the main alternative diagnoses, including inherited bone marrow failure disorders, hypocellular myelodysplastic syndromes, acute leukemias with hypoplastic presentation, and selective lineage aplasias. The quality of the initial diagnostic evaluation directly determines the choice between transplantation and immunosuppression and affects the risk of early and late complications.
Treatment of aplastic anemia is time dependent and guided by age, severity, comorbidities, donor availability, and probability of response to immunosuppression. In severe and very severe forms, the immediate goal is to reduce mortality from infection and hemorrhage by restoring effective hematopoiesis; in nonsevere forms, the approach may include a period of active observation with supportive care and close monitoring, provided that hematologic values and the clinical profile are stable and there are no significant infections or bleeding.
In young patients with an HLA matched sibling donor, allogeneic hematopoietic stem cell transplantation often represents the option with the greatest probability of definitive cure. The choice of conditioning regimen and GVHD prevention must take toxicity risk into account and, when telomere biology disorders or other inherited forms are suspected, require dedicated strategies to avoid excessive organ toxicity.
In patients aged 40 years or younger with acquired severe or very severe aplastic anemia, an HLA matched unrelated donor may be considered from first line treatment as an alternative to immunosuppression, according to donor availability, clinical profile, and specialist transplant assessment.
In the absence of a suitable donor or in patients who are not candidates for upfront transplantation, immunosuppression is the standard. The reference regimen for severe disease uses antithymocyte globulin, preferably horse ATG when available within reference protocols, combined with cyclosporine. Introduction of thrombopoietin receptor agonists, particularly eltrombopag, in combination with baseline immunosuppression has significantly improved hematologic response rates and the probability of multilineage recovery, changing the natural history of the disease in a substantial proportion of patients. Management requires close monitoring for toxicity, drug interactions, and the course of cytopenias, together with early assessment of response to identify nonresponders.
In refractory or relapsed SAA/VSAA after initial immunosuppression, second line treatment must be planned early: the decision should be made within approximately 6 months after ATG, and the choice, based on age, donor availability, and whether the disease is refractory or relapsing, must be between allogeneic transplantation and a second course of ATG based immunosuppressive therapy.
Supportive care is an integral part of treatment at every stage. It includes red blood cell and platelet transfusions according to clinical indication, preferably using leukoreduced and, when appropriate, irradiated blood components to reduce specific risks. A rigorous strategy for preventing and managing infections is essential: patient education, rapid access to care in the event of fever, prompt empiric antimicrobials for febrile neutropenia, and, in selected cases, antimicrobial prophylaxis according to the risk and duration of neutropenia. Management of iron overload from repeated transfusions and prevention of alloimmunization require advance planning because they affect quality of life and future options, including transplantation.
Prognosis has improved radically with transplantation and modern immunosuppression. Long term survival is now high in many subgroups but depends on age, initial severity, timely access to therapy, hematologic response, and early infectious or hemorrhagic complications. During follow-up, the main prognostic determinants include risk of relapse after immunosuppression, the need for salvage therapies, and especially the risk of clonal evolution to PNH, myelodysplasia, or acute leukemia. Hematologic follow-up must therefore be continuous and focused not only on blood counts but also on clonal biology and early signs of transformation.
Complications arise primarily from neutropenia and thrombocytopenia, which determine mortality and morbidity in the early stages. Bacterial and fungal infections may progress rapidly to sepsis and respiratory failure, particularly with profound neutropenia, and may present with attenuated signs; this requires an aggressive clinical approach and a low threshold for starting empiric therapy and rapid diagnostic pathways. Invasive fungal infections are a particular threat during prolonged neutropenia and require a high level of clinical and radiologic vigilance.
Hemorrhagic complications reflect the depth of thrombocytopenia and concomitant mucosal fragility or infection. Petechiae and ecchymoses may precede more significant bleeding; in severe forms, gastrointestinal and intracranial hemorrhages are critical events requiring prevention through close monitoring and appropriate transfusion support, integrated with correction of cofactors and management of comorbidities.
In the medium and long term, one of the most important complications is clonal evolution. The appearance or expansion of PNH clones may alter the clinical picture through hemolysis and thrombosis, whereas the emergence of cytogenetic abnormalities or somatic mutations associated with myelodysplasia may precede transformation to myelodysplastic syndrome or acute leukemia. This risk is heterogeneous and depends in part on the mutational profile and the course of cytopenias over time, making scheduled monitoring with repeat bone marrow assessments necessary when indicated.
The therapies themselves contribute to complications. Immunosuppression may promote opportunistic infections and viral reactivations, as well as organ toxicity, particularly nephrotoxicity and hypertension with cyclosporine. After transplantation, GVHD and infections related to posttransplant immunosuppression are major complications and may affect quality of life and survival. Repeated transfusions may cause alloimmunization and platelet refractoriness, as well as iron overload with progressive organ damage if not recognized and managed. Prevention and early diagnosis of these complications are an integral part of care and must be planned from the initial evaluation.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.